Jin Rong Jie·2026-03-17 10:21Core Viewpoint - The significant drop in the stock price of Zhaoyan New Drug is attributed to a large-scale share reduction announcement by major shareholders, leading to a market capitalization decline of over 20.53 billion yuan in a single day [1]. Group 1: Shareholder Actions - Major shareholders Gu Xiaolei and Gu Meifang plan to reduce their holdings by a total of 30.74 million shares, representing 4.1026% of the company's total share capital, from March 20, 2026, to June 19, 2026 [1]. - The reduction is primarily driven by personal financial needs, with the estimated value of the shares to be sold amounting to approximately 840 million yuan based on the closing price on March 16 [1]. - The Gu family, which has historical ties to the company, has been reducing their stakes since the company's IPO, with previous reductions noted in 2018 and 2022 [2][4]. Group 2: Company Performance - Zhaoyan New Drug's main business is underperforming, with a projected revenue decline of approximately 13.9% to 22.1% for 2025 compared to 2024, despite a significant increase in net profit [6]. - The expected net profit for 2025 is projected to be between 233 million and 349 million yuan, a substantial increase of 214% to 371% compared to 2024 [6]. - The increase in net profit is largely attributed to the appreciation of biological assets, particularly laboratory monkeys, which have seen a rebound in prices after a previous decline [7]. Group 3: Market Reactions - The stock market reacted negatively to the news of shareholder reductions, with Zhaoyan New Drug's stock price dropping by 10.01% to 29.32 yuan per share, reaching the daily limit down [1]. - The overall market sentiment appears to be influenced by the ongoing sell-off by major shareholders, leading to a loss of confidence among retail investors [8].